| 名稱 | ADCC Bioassay Effector Cell F variant （Low Affinit |
| 型號 | CBP74002 |
| 報價 |  |
| 特點 | ADCC Bioassay Effector Cell F variant （Low Affinity）- Fcγ-NFAT/Jurkat,母細胞：Jurkat，培養基：1640+10%FBS |
產品搜索
相關文章
聯系我們
產品展示 / PRODUCTS
- 詳細內容
| I. Background | |
抗體依賴的細胞介導的細胞毒性作用（ADCC，antibody-dependent cell-mediated cytotoxicity ）是指抗體的 Fab 段結合病毒感染的細胞或腫瘤細胞的抗原表位，其 Fc 段與殺 傷細胞（NK 細胞、巨噬細胞等）表面的 FcR 結合，介導殺傷細胞直接殺傷靶細胞，它是 抗腫瘤的治療性抗體藥物發生作用的一種作用重要機制。 | |
| II. Description | |
ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat 報告基因藥靶模型 很好的模擬了體內 ADCC 的信號轉導過程，原理見下圖所示。
| |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-CD16(F158) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS |
| Mycoplasma Testing: | Negative |
| Storage: | Immediately upon receipt, store in liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Recombinant ADCC Bioassay Effector Cell F variant (Low Affinity)- Fcγ-NFAT/Jurkat expressing CD16.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat (C11) with Raji.
" _ue_custom_node_="true">
